Elmind Capital LP bought a new position in Design Therapeutics, Inc. (NASDAQ:DSGN – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 207,900 shares of the company’s stock, valued at approximately $1,950,000. Design Therapeutics comprises approximately 0.6% of Elmind Capital LP’s portfolio, making the stock its 28th biggest holding. Elmind Capital LP owned 0.36% of Design Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in DSGN. Torren Management LLC bought a new position in Design Therapeutics in the 4th quarter worth about $26,000. Russell Investments Group Ltd. boosted its holdings in shares of Design Therapeutics by 69.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company’s stock worth $48,000 after purchasing an additional 2,618 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Design Therapeutics by 26.8% in the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock worth $48,000 after purchasing an additional 3,033 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Design Therapeutics in the 4th quarter worth about $67,000. Finally, Jane Street Group LLC purchased a new position in shares of Design Therapeutics in the 1st quarter worth about $70,000. 56.64% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research firms have recently issued reports on DSGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a report on Monday, April 20th. Oppenheimer upped their price objective on Design Therapeutics from $18.00 to $21.00 and gave the stock an “outperform” rating in a report on Monday, May 4th. Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective on shares of Design Therapeutics in a report on Wednesday, April 29th. Finally, Jefferies Financial Group assumed coverage on Design Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $15.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Design Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.50.
Design Therapeutics Price Performance
Shares of DSGN stock opened at $11.93 on Thursday. The stock has a market capitalization of $745.15 million, a PE ratio of -9.94 and a beta of 1.63. Design Therapeutics, Inc. has a 1-year low of $3.33 and a 1-year high of $17.25. The business has a 50-day moving average of $12.27 and a 200 day moving average of $10.80.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.07. Analysts anticipate that Design Therapeutics, Inc. will post -1.36 EPS for the current year.
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
Featured Stories
- Five stocks we like better than Design Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN – Free Report).
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
